160 related articles for article (PubMed ID: 29694635)
1. Outcomes of patients with bone metastases from differentiated thyroid cancer.
Califano I; Deutsch S; Löwenstein A; Cabezón C; Pitoia F
Arch Endocrinol Metab; 2018 Feb; 62(1):14-20. PubMed ID: 29694635
[TBL] [Abstract][Full Text] [Related]
2. Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases.
Zunino A; Pitoia F; Faure E; Reyes A; Sala M; Sklate R; Ilera V; Califano I;
Endocrine; 2019 Sep; 65(3):630-636. PubMed ID: 31327159
[TBL] [Abstract][Full Text] [Related]
3. Improved Survival After Multimodal Approach with
Wu D; Gomes Lima CJ; Moreau SL; Kulkarni K; Zeymo A; Burman KD; Wartofsky L; Van Nostrand D
Thyroid; 2019 Jul; 29(7):971-978. PubMed ID: 31017051
[No Abstract] [Full Text] [Related]
4. Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival.
Jannin A; Lamartina L; Moutarde C; Djennaoui M; Lion G; Chevalier B; Vantyghem MC; Deschamps F; Hadoux J; Baudin E; Schlumberger M; Leboulleux S; Do Cao C
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2401-2413. PubMed ID: 35149914
[TBL] [Abstract][Full Text] [Related]
5. LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA AND BONE METASTASES.
Slook O; Levy S; Slutzky-Shraga I; Tsvetov G; Robenshtok E; Shimon I; Benbassat C; Hirsch D
Endocr Pract; 2019 May; 25(5):427-437. PubMed ID: 30657361
[No Abstract] [Full Text] [Related]
6. Clinical management and outcomes in patients with hyperfunctioning distant metastases from differentiated thyroid cancer after total thyroidectomy and radioactive iodine therapy.
Qiu ZL; Shen CT; Luo QY
Thyroid; 2015 Feb; 25(2):229-37. PubMed ID: 25331724
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.
Lang BH; Wong KP; Cheung CY; Wan KY; Lo CY
Ann Surg Oncol; 2013 Apr; 20(4):1329-35. PubMed ID: 23104708
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome after bone metastasis (BM) surgery in patients with differentiated thyroid carcinoma (DTC): a retrospective study of 40 cases.
Nakayama R; Horiuchi K; Susa M; Watanabe I; Watanabe K; Tsuji T; Matsumoto M; Toyama Y; Morioka H
Jpn J Clin Oncol; 2014 Oct; 44(10):918-25. PubMed ID: 25104791
[TBL] [Abstract][Full Text] [Related]
9. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
10. Brain metastases from thyroid carcinoma: a retrospective study of 21 patients.
Henriques de Figueiredo B; Godbert Y; Soubeyran I; Carrat X; Lagarde P; Cazeau AL; Italiano A; Sargos P; Kantor G; Loiseau H; Bonichon F
Thyroid; 2014 Feb; 24(2):270-6. PubMed ID: 23734630
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes and prognostic factors in patients with no less than three distant organ system metastases from differentiated thyroid carcinoma.
Zhang XY; Sun JW; Qiu ZL; Wang Y; Chen XY; Zhao JH; Luo QY
Endocrine; 2019 Nov; 66(2):254-265. PubMed ID: 31317522
[TBL] [Abstract][Full Text] [Related]
12. LONG-TERM OUTCOMES AND PROGNOSTIC FACTORS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER AND DISTANT METASTASES.
Hirsch D; Levy S; Tsvetov G; Gorshtein A; Slutzky-Shraga I; Akirov A; Robenshtok E; Shimon I; Benbassat CA
Endocr Pract; 2017 Oct; 23(10):1193-1200. PubMed ID: 28704099
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas.
Wassermann J; Bernier MO; Spano JP; Lepoutre-Lussey C; Buffet C; Simon JM; Ménégaux F; Tissier F; Leban M; Leenhardt L
Oncologist; 2016 Jan; 21(1):50-8. PubMed ID: 26675742
[TBL] [Abstract][Full Text] [Related]
14. Progression free survival related to
Zhu X; Wu S; Yuan X; Wang H; Ma C
Hell J Nucl Med; 2019; 22(2):123-130. PubMed ID: 31273354
[TBL] [Abstract][Full Text] [Related]
15. Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience.
Mazziotti G; Formenti AM; Panarotto MB; Arvat E; Chiti A; Cuocolo A; Dottorini ME; Durante C; Agate L; Filetti S; Felicetti F; Filice A; Pace L; Pellegrino T; Rodari M; Salvatori M; Tranfaglia C; Versari A; Viola D; Frara S; Berruti A; Giustina A; Giubbini R
Endocrine; 2018 Jan; 59(1):90-101. PubMed ID: 29110129
[TBL] [Abstract][Full Text] [Related]
16. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland.
Nixon IJ; Whitcher MM; Palmer FL; Tuttle RM; Shaha AR; Shah JP; Patel SG; Ganly I
Thyroid; 2012 Sep; 22(9):884-9. PubMed ID: 22827579
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
18. FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma.
Kang SY; Bang JI; Kang KW; Lee HY; Chung JK
PLoS One; 2019; 14(6):e0218416. PubMed ID: 31237886
[TBL] [Abstract][Full Text] [Related]
19. Unexpected radioactive iodine accumulation on whole-body scan after I-131 ablation therapy for differentiated thyroid cancer.
Iwano S; Ito S; Kamiya S; Ito R; Kato K; Naganawa S
Nagoya J Med Sci; 2020 May; 82(2):205-215. PubMed ID: 32581401
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
